DAEWON PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14,960 KRW | -0.07% |
|
-1.77% | -4.47% |
| Sales 2024 * | 604B 436M 600M | Sales 2025 * | 592B 428M 589M | Capitalization | 317B 229M 315M |
|---|---|---|---|---|---|
| Net income 2024 * | 32B 23.1M 31.81M | Net income 2025 * | 39B 28.16M 38.77M | EV / Sales 2024 * | 0.6 x |
| Net Debt 2024 * | 42.7B 30.83M 42.44M | Net Debt 2025 * | 18.7B 13.5M 18.59M | EV / Sales 2025 * | 0.57 x |
| P/E ratio 2024 * |
10.4
x | P/E ratio 2025 * |
8.46
x | Employees | 1,125 |
| Yield 2024 * |
2.34% | Yield 2025 * |
2.34% | Free-Float | 57.37% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.07% | ||
| 1 week | -1.77% | ||
| Current month | +0.40% | ||
| 1 month | +0.40% | ||
| 3 months | +1.01% | ||
| 6 months | -3.17% | ||
| Current year | -4.47% |
1 week
14 870.00
15 200.00
1 month
13 940.0015 640.00
Current year
13 940.0016 300.00
1 year
13 530.0019 490.00
3 years
13 300.9723 640.78
5 years
8 710.1229 958.39
10 years
7 526.0329 958.39
| Managers | Title | Age | Since |
|---|---|---|---|
Seung-Yul Baek
CEO | Chief Executive Officer | 65 | - |
Seung-Ho Baek
CEO | Chief Executive Officer | 68 | - |
Tae-Hong Choi
PSD | President | 67 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Ho Baek
CEO | Chief Executive Officer | 68 | - |
Seung-Yul Baek
CEO | Chief Executive Officer | 65 | - |
Jonathan In Baek
BRD | Director/Board Member | 40 | 13-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 14,960 | -0.07% | 30,054 |
| 24-04-29 | 14,970 | +0.27% | 20,133 |
| 24-04-26 | 14,930 | -1.13% | 37,984 |
| 24-04-25 | 15,100 | +0.20% | 37,799 |
| 24-04-24 | 15,070 | -0.20% | 52,364 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Daewon Pharmaceutical Co., Ltd. is a Korea-based company mainly engaged in the manufacture of pharmaceutical products. The Companyâs products include antipyretics, analgesics, anti-inflammatory drugs, respiratory drugs, gastrointestinal drugs, antimicrobial drugs, cardiovascular drugs, metabolic drugs, psychoneurotic drugs, neuromuscular drugs, endocrine drugs and others. The Company also produces multivitamins and health foods. The Company distributes its products within domestic market and overseas markets, including Vietnam, Myanmar, Southeast Asia, the Middle East and others.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
14,960
KRW
Average target price
21,000
KRW
Spread / Average Target
+40.37%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.47% | 229M | |
| +33.25% | 704B | |
| +28.59% | 577B | |
| -3.55% | 348B | |
| +18.16% | 327B | |
| +4.36% | 288B | |
| +14.81% | 234B | |
| +4.93% | 198B | |
| -9.78% | 194B | |
| -3.69% | 147B |
- Stock Market
- Equities
- A003220 Stock
